^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NUV-868

    i
    Other names: NUV-868, NUV868, NUV 868
    Associations

    News

    Trials
    Company:
    Nuvation Bio
    Drug class:
    BRD4 inhibitor, BET-BD2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=657, Recruiting, Nuvation Bio Inc. | N=246 --> 657 | Trial completion date: Feb 2026 --> Nov 2026 | Trial primary completion date: Jan 2026 --> Jun 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    BRCA (Breast cancer early onset)
    |
    Lynparza (olaparib) • Xtandi (enzalutamide) • NUV-868
    almost2years
    NUV-868, a novel BD2-selective BET inhibitor, in combination with enzalutamide or olaparib, inhibits growth of solid tumor xenografts (AACR 2023)
    Our preclinical data demonstrate that NUV-868, a BD2-selective BET inhibitor, inhibits growth of tumor xenografts in combination with enzalutamide or olaparib and provides rationale for examination of these combinations in the clinic. An ongoing, phase 1 clinical study (NCT05252390) is evaluating NUV-868 as a monotherapy and in combination with olaparib or enzalutamide in patients with advanced solid tumors.
    Combination therapy • PARP Biomarker
    |
    BRD4 (Bromodomain Containing 4)
    |
    Lynparza (olaparib) • Xtandi (enzalutamide) • NUV-868
    over2years
    NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=246, Recruiting, Nuvation Bio Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA mutation
    |
    Lynparza (olaparib) • Xtandi (enzalutamide) • NUV-868
    almost3years
    NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=246, Not yet recruiting, Nuvation Bio Inc.
    New P1/2 trial • Combination therapy
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA mutation
    |
    Lynparza (olaparib) • Xtandi (enzalutamide) • NUV-868